Skip to content
ES
MARKETS / NASDAQ / SVA
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Sinovac Biotech Ltd. SVA

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$386.0M
▲ 6.8% YoY
$-198.8M
▼ 589.1% YoY
$-561.1M
In brief

What this company does

Sinovac Biotech Ltd., through its operating subsidiaries, is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases. Its vaccine portfolio covers hepatitis A, hepatitis B, hand, foot and mouth disease caused by enterovirus 71, seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. Its Healive hepatitis A vaccine production line has an annual capacity of approximately 20 million doses. The company conducts its business principally through its operating subsidiaries Sinovac Beijing, Sinovac LS and Sinovac Dalian, and its wholly owned subsidiaries Sinovac Biomed, Sinovac Hong Kong and Sinovac Singapore. In the Haidian District of Beijing, the company owns and operates facilities in the Peking University Biological Industry Park totaling 122,203 square feet, including its corporate headquarters and the production plant for Healive and Bilive. Sinovac Antigua was incorporated on March 1, 1999 in Antigua and Barbuda as an international business corporation, and was known as Net-Force System Inc. and engaged in the online gaming business before adopting its current name on October 21, 2003.

Written from the business description in SINOVAC BIOTECH LTD's annual report to the U.S. Securities and Exchange Commission, filed 5 June 2026. Every sentence was checked against that document before publication.

Growth
USD 386.0M
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.4 · Net income -0.2
8B16B200920112013201520172019202120232025
Compound annual growth
−36.0%
−5.4%
+19.1%
+17.7%
+142.6%
+59.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −5.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−52 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -127.0% · Net -51.5%
50%-50%-100%-150%200920112013201520172019202120232025
ROE
FY2023 · ROE -0.2%
50%100%150%200920112013201520172019202120232025
Gross margin67.9%
Operating margin-127.0%
Net margin-51.5%
Return on assets-1.9%
EBITDAUSD -392.7M

Cash & shareholders
USD 3.5B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF -0.6
5B10B200920112013201520172019202120232025
Net buybacks $B Dividends $B
FY2025 · Dividends 3.5 · Net buybacks —
2B200920112019202120232025
Dividends paidUSD 3.5B
Net buybacks—
Share of profit—
Consecutive raises—

USD 3.5B in dividends went back to shareholders.

Total assetsUSD 8.5B
EquityUSD 4.4B
CashUSD 488.2M
Gross debtUSD 494.9M
Net debtUSD 6.6M
Current ratio4.59×

Net debt stands at 0% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.40.40.51.519.40.50.20.20.20.10.10.10.10.00.10.00.1
Operating income $B−0.5−0.5−0.7−0.517.60.20.10.00.00.00.00.00.0−0.00.0−0.00.0
EBITDA $B−0.4−0.4−0.6−0.417.70.20.10.10.10.00.00.00.0−0.00.0−0.00.0
Income tax $B−0.10.00.00.03.40.00.00.00.00.00.00.0−0.0−0.00.0−0.00.0
Net income $B−0.20.0−0.10.08.10.10.00.00.0−0.0−0.0−0.00.0−0.0−0.0−0.00.0
Free cash flow $B−0.6−0.2−0.0−1.114.70.50.00.00.0−0.0−0.0−0.00.0−0.0−0.0−0.00.0
EPS, diluted $−0.831.27−0.190.20113.440.970.410.340.45−0.01−0.03−0.030.13−0.27−0.02−0.160.46
Dividend / sh $55.00················
Payout %··−243217102300·······−694−3919
ROE %··−0.20.2166.821.216.410.819.3−0.5−1.1−1.26.0·−0.7−6.7·
Shares out B0.070.070.070.070.070.100.100.070.060.060.060.060.060.060.050.05·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 84 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 11 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code B9
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image